Related references
Note: Only part of the references are listed.PD-L1 status in breast cancer: Current view and perspectives
Semir Vranic et al.
SEMINARS IN CANCER BIOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Correlation of Insulin-like Growth Factor 1 Receptor Expression With Different Molecular Subtypes of Breast Cancer in the UAE
Noura Alkhayyal et al.
ANTICANCER RESEARCH (2020)
Directing Traffic: How to Effectively Drive T Cells into Tumors
Annabelle J. Anandappa et al.
CANCER DISCOVERY (2020)
Molecular Biological Features of Nottingham Histological Grade 3 Breast Cancers
Hideo Takahashi et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Tumor-infiltrating lymphocytes (TILs) in ER+/HER2-breast cancer
C. Criscitiello et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Association between levels of tumor-infiltrating lymphocytes in different subtypes of primary breast tumors and prognostic outcomes: a meta-analysis
Lin He et al.
BMC WOMENS HEALTH (2020)
IDO Expression in Cancer: Different Compartment, Different Functionality?
Annabel Meireson et al.
FRONTIERS IN IMMUNOLOGY (2020)
Prognosis of PD-L1 in human breast cancer: protocol for a systematic review and meta-analysis
Isnard Elman Litvin et al.
SYSTEMATIC REVIEWS (2020)
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F. Cardoso et al.
ANNALS OF ONCOLOGY (2019)
Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas
M. Lisa Zhang et al.
MODERN PATHOLOGY (2019)
Mechanisms of immune evasion in breast cancer
Joshua P. Bates et al.
BMC CANCER (2018)
Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer
Fangxuan Li et al.
CANCER BIOLOGY & THERAPY (2018)
IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1
Erik A. Dill et al.
MODERN PATHOLOGY (2018)
Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised Medicine
Mohammed A. Aleskandarany et al.
PATHOBIOLOGY (2018)
Targeting the IDO1 pathway in cancer: from bench to bedside
Ming Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Breast Cancer Immunotherapy: Facts and Hopes
Leisha A. Emens
CLINICAL CANCER RESEARCH (2018)
High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients
NiJiati AiErken et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2017)
The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer
Hitomi Mori et al.
ONCOTARGET (2017)
Strong Correlation of Indoleamine 2,3-Dioxygenase 1 Expression with Basal-Like Phenotype and Increased Lymphocytic Infiltration in Triple-Negative Breast Cancer
Sewha Kim et al.
JOURNAL OF CANCER (2017)
Clinical significance of tumor-infiltrating lymphocytes in breast cancer
Sasha E. Stanton et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
IDO is highly expressed in breast cancer and breast cancer-derived circulating microvesicles and associated to aggressive types of tumors by in silico analysis
M. T. Isla Larrain et al.
TUMOR BIOLOGY (2014)
Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry
Hatem Soliman et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cancer immunoediting from immune surveillance to immune escape
Ryungsa Kim et al.
IMMUNOLOGY (2007)
B7-h1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression
J Konishi et al.
CLINICAL CANCER RESEARCH (2004)
Share Paper
